Want to see ISPC full AI Analyst Report?
Top Page
iSpecimen
(NASDAQ:ISPC)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▲(383.87% Upside)
Action:Reiterated
Date:08/22/26
The score is driven primarily by very weak financial performance (sharp revenue decline, negative gross profit, and sustained cash burn with shrinking equity). Technicals also weigh on the score with the price below key moving averages and negative MACD. Valuation is constrained by ongoing losses and no dividend support, while recent corporate events are mixed (capital raise helps liquidity but Nasdaq noncompliance increases risk).
Positive Factors
Scalable marketplace execution
The project demonstrates that iSpecimen can coordinate complex, high-volume biospecimen sourcing and international fulfillment. Reliable execution at scale can strengthen customer trust, support repeat research programs, and reinforce the value of its supplier network.
Negative Factors
Severe revenue deterioration
A prolonged revenue contraction signals weakening demand, customer activity, or execution within the marketplace. Lower scale makes fixed technology and operating costs harder to absorb, limiting the company’s ability to achieve sustainable margins without renewed growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Scalable marketplace execution
The project demonstrates that iSpecimen can coordinate complex, high-volume biospecimen sourcing and international fulfillment. Reliable execution at scale can strengthen customer trust, support repeat research programs, and reinforce the value of its supplier network.
Read all positive factors
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.26M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth-92.11%
EPS Growth86.78%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,518,590
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iSpecimen Business Overview & Revenue Model
Company Description
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate a...
How the Company Makes Money
iSpecimen primarily makes money by facilitating transactions between research customers (such as pharmaceutical companies, biotechnology companies, and academic or government laboratories) and a network of specimen suppliers (such as hospitals, pa...
iSpecimen Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 466.30K | 1.93M | 9.29M | 9.93M | 10.40M | 11.14M |
| Gross Profit | -504.83K | 24.11K | 3.99M | 5.11M | 5.65M | 5.89M |
| EBITDA | -10.25M | -8.75M | -10.38M | -8.80M | -8.80M | -5.86M |
| Net Income | -11.42M | -10.49M | -12.50M | -11.10M | -10.25M | -8.96M |
Balance Sheet | ||||||
| Total Assets | 7.39M | 9.53M | 9.35M | 15.82M | 24.62M | 35.72M |
| Cash, Cash Equivalents and Short-Term Investments | 4.41M | 6.88M | 1.88M | 5.01M | 15.31M | 27.74M |
| Total Debt | 240.90K | 268.80K | 312.17K | 196.24K | 185.85K | 3.42M |
| Total Liabilities | 5.66M | 6.44M | 6.04M | 6.08M | 4.31M | 5.93M |
| Stockholders Equity | 1.74M | 3.09M | 3.31M | 9.74M | 20.31M | 29.79M |
Cash Flow | ||||||
| Free Cash Flow | -8.00M | -4.24M | -8.30M | -10.55M | -9.01M | -11.71M |
| Operating Cash Flow | -7.00M | -4.24M | -8.26M | -5.81M | -5.82M | -10.67M |
| Investing Cash Flow | -1.00M | -1.00M | 1.98M | -7.23M | -3.19M | -1.04M |
| Financing Cash Flow | 12.53M | 10.24M | 5.82M | 70.89K | -3.42M | 38.75M |
iSpecimen Technical Analysis
Negative
0.31
Price Trends
2.33
Negative
3.45
Negative
8.96
Negative
Market Momentum
-0.06
Negative
34.13
Neutral
38.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.33, and below the 200-day MA of 8.96, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 34.13 is Neutral, neither overbought nor oversold. The STOCH value of 38.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.
iSpecimen Risk Analysis
iSpecimen disclosed 74 risk factors in its most recent earnings report. iSpecimen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
iSpecimen Peers Comparison
UnderperformOutperform
Sector (51)
ISPC
iSpecimen
1.69
-31.23
-94.87%
INBS
Intelligent Bio Solutions
2.51
-12.19
-82.93%
BGLC
BioNexus Gene Lab Corp
1.59
-4.05
-71.81%
BIAF
bioAffinity Technologies, Inc.
0.40
-7.08
-94.65%
iSpecimen Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
iSpecimen Engages IR Agency for Investor Marketing
Neutral
Aug 14, 2026
On August 12, 2026, iSpecimen Inc. entered into a three-month Consulting Agreement with IR Agency LLC to provide non-exclusive marketing and advertising services aimed at communicating information about the company to the financial community. The ...
Business Operations and StrategyFinancial DisclosuresLegal Proceedings
iSpecimen Settles Arbitration and Terminates WestPark Agreements
Neutral
Aug 11, 2026
On August 6, 2026, iSpecimen entered into a Settlement Agreement and Mutual Release with WestPark Capital to resolve an arbitration stemming from investment banking engagement agreements related to WestPark’s role as underwriter for iSpecime...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
iSpecimen Completes $5 Million Public Offering
Positive
Aug 7, 2026
On August 5, 2026, iSpecimen Inc. entered into agreements with E.F. Hutton Co. and participating investors for a “reasonable best efforts” public offering comprising 996,231 shares of common stock and pre-funded warrants to purchase u...
Business Operations and StrategyProduct-Related Announcements
iSpecimen advances digital transformation with Milestone 3 completion
Positive
Jul 15, 2026
On July 9, 2026, iSpecimen Inc. completed Milestone 3 in its digital transformation program powered by SalesStack Solutions, triggering a $700,000 payment under its software purchase and services agreement. The new milestone adds marketplace featu...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
iSpecimen Receives Nasdaq Noncompliance Notice, Listing at Risk
Negative
Jun 1, 2026
On May 29, 2026, iSpecimen Inc. disclosed that it received a Nasdaq notice stating the company no longer meets the exchange’s minimum stockholders’ equity requirement of $2.5 million, having reported equity of $814,038 as of March 31, ...
Executive/Board ChangesShareholder Meetings
iSpecimen Shareholders Approve Director, Auditor and Incentive Plan
Positive
May 29, 2026
At its reconvened 2025 Annual Meeting of Stockholders held on May 29, 2026, iSpecimen reported that a quorum representing about 35% of its 8.48 million eligible common shares was present or represented by proxy, allowing the company to proceed wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.